AbbVie has successfully navigated the loss of patent exclusivity for its top-selling drug, Humira, and continues to thrive. Eli Lilly offers strong growth potential and a solid dividend, with a diverse portfolio of approved drugs. Johnson & Johnson, with a strong balance sheet and diversified product offerings, remains resilient despite legal and regulatory challenges. These three healthcare stocks are recommended for long-term investment by Motley Fool contributors.

Read more at Yahoo Finance: 3 Stocks to Buy and Hold Forever